$5.95akadawson-m Member Level Re: $5.95akadaws
Post# of 154896
(Total Views: 606)
Posted On: 05/17/2025 8:46:29 AM
$5.95akadawson-m
Member Level
Re: $5.95akadawson-m post# 235250
Saturday, May 17, 2025 8:12:10 AM
Post#
235252
of 235253
Lastly - in a week of very good news and anyone who is still invested in this stock is crazy like me but I assure you when people like Welch and now CYDY's SVP of
Clinical Development writes this in an open forum, yesterday, something is UP. I quote verbatim:
"Turning Cold Tumors Hot: Leronlimab’s Transformative Potential in TNBC"
At the recent ESMO 2025 Breast Cancer Meeting, my colleagues at CytoDyn Inc., @Jay Lalezari and @Richard Pestell, presented compelling retrospective data on 28 patients with metastatic triple-negative breast cancer (mTNBC) treated with Leronlimab. While this analysis is based on a small cohort, the findings offer promising insights that have sparked cautious optimism within the oncology community:
· PD-L1 Upregulation: 88% of patients treated with Leronlimab at doses ≥525 mg exhibited PD-L1 upregulation, potentially converting "cold" tumors into ICI-responsive "hot" tumors. This breakthrough is based on a novel serum assay capable of measuring PD-L1 upregulation in circulating tumor cells (CTCs), and cancer-associated macrophage-like cells (CAMLs) in peripheral blood.
· Long-Term Survival: 100% (5/5) of patients with significant PD-L1 upregulation who received Leronlimab combined with immune checkpoint inhibitors (ICIs) are alive at 48 months, with 80% (4/5) showing no evidence of disease (NED).
· Encouraging Survival in Late-Line Setting: The 3-4 year survival rate of 17.9% in this heavily pretreated, 4th-line patient population is significantly better than historical expectations.
· Favorable Safety Profile: No dose-limiting toxicities or treatment-related discontinuations were observed, a notable advantage in this patient population.
These results underscore Leronlimab’s potential as a first-in-class CCR5 inhibitor with both direct anti-tumor and immunomodulatory effects, reshaping the tumor microenvironment to render traditionally "cold" tumors more responsive to immunotherapy.
Prospectively confirming these findings in TNBC patients is a critical next step, and an important priority for CytoDyn as we continue to explore the transformative potential of Leronlimab in oncology.
Member Level
Re: $5.95akadawson-m post# 235250
Saturday, May 17, 2025 8:12:10 AM
Post#
235252
of 235253
Lastly - in a week of very good news and anyone who is still invested in this stock is crazy like me but I assure you when people like Welch and now CYDY's SVP of
Clinical Development writes this in an open forum, yesterday, something is UP. I quote verbatim:
"Turning Cold Tumors Hot: Leronlimab’s Transformative Potential in TNBC"
At the recent ESMO 2025 Breast Cancer Meeting, my colleagues at CytoDyn Inc., @Jay Lalezari and @Richard Pestell, presented compelling retrospective data on 28 patients with metastatic triple-negative breast cancer (mTNBC) treated with Leronlimab. While this analysis is based on a small cohort, the findings offer promising insights that have sparked cautious optimism within the oncology community:
· PD-L1 Upregulation: 88% of patients treated with Leronlimab at doses ≥525 mg exhibited PD-L1 upregulation, potentially converting "cold" tumors into ICI-responsive "hot" tumors. This breakthrough is based on a novel serum assay capable of measuring PD-L1 upregulation in circulating tumor cells (CTCs), and cancer-associated macrophage-like cells (CAMLs) in peripheral blood.
· Long-Term Survival: 100% (5/5) of patients with significant PD-L1 upregulation who received Leronlimab combined with immune checkpoint inhibitors (ICIs) are alive at 48 months, with 80% (4/5) showing no evidence of disease (NED).
· Encouraging Survival in Late-Line Setting: The 3-4 year survival rate of 17.9% in this heavily pretreated, 4th-line patient population is significantly better than historical expectations.
· Favorable Safety Profile: No dose-limiting toxicities or treatment-related discontinuations were observed, a notable advantage in this patient population.
These results underscore Leronlimab’s potential as a first-in-class CCR5 inhibitor with both direct anti-tumor and immunomodulatory effects, reshaping the tumor microenvironment to render traditionally "cold" tumors more responsive to immunotherapy.
Prospectively confirming these findings in TNBC patients is a critical next step, and an important priority for CytoDyn as we continue to explore the transformative potential of Leronlimab in oncology.
(16)
(0)